SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) financials
SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
- Market Cap: ₹2,465Cr.
- Current Price: ₹55.9
- Stock P/E: 68.4
- ROE: 28.9%
- ROCE: 36.9%
- Book Value: ₹2.05
- Dividend Yield: 0.02%
- 52W High / Low: ₹65.3/26.3
In Jun 2026, SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) reported sales ₹24 Cr and net profit ₹15 Cr.
Annual TTM: sales ₹75 Cr, net profit ₹36 Cr.
Shareholding: Promoters 51.16% (Aug 2026), DIIs 0.11% (Aug 2026), Public 48.74% (Aug 2026), No. of Shareholders 28,384% (Aug 2026).
| Category | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 6 | 11 | 13 | 5 | 6 | 39 | 6 | 24 |
| Expenses | 5 | 7 | 6 | 4 | 6 | 12 | 6 | 2 |
| Operating Profit | 1 | 4 | 7 | 1 | -0 | 27 | 1 | 21 |
| OPM % | 12% | 37% | 55% | 24% | -7% | 69% | 11% | 90% |
| Other Income | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 4 | 8 | 1 | 0 | 27 | 0 | 20 |
| Tax % | 39% | 23% | 29% | 26% | -1,090% | 24% | 568% | 26% |
| Net Profit | 1 | 3 | 5 | 1 | 2 | 20 | -2 | 15 |
| EPS in Rs | 0.01 | 0.07 | 0.12 | 0.02 | 0.05 | 0.46 | -0.04 | 0.34 |
| Raw PDF | — | — | — | — | — | — | — | — |
| Category | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 12 | 11 | 20 | 59 | 75 | 33 | 57 | 75 |
| Expenses | 10 | 10 | 18 | 53 | 55 | 20 | 28 | 26 |
| Operating Profit | 2 | 1 | 3 | 5 | 19 | 13 | 29 | 49 |
| OPM % | 13% | 13% | 14% | 9% | 26% | 39% | 51% | 65% |
| Other Income | 0 | 0 | 0 | 1 | 3 | 4 | 5 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 |
| Profit before tax | 0 | 0 | 1 | 4 | 20 | 13 | 29 | 48 |
| Tax % | 82% | -90% | 26% | 1% | 7% | 28% | 23% | — |
| Net Profit | 0 | 0 | 1 | 4 | 19 | 10 | 22 | 36 |
| EPS in Rs | 0.00 | 0.00 | 0.02 | 0.10 | 0.42 | 0.22 | 0.50 | 0.81 |
| Dividend Payout % | 0% | 0% | 10% | 4% | 6% | 5% | 2% | — |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 4 | 11 | 44 | 44 |
| Reserves | 14 | 14 | 14 | 15 | 21 | 47 | 19 | 46 |
| Borrowings | 6 | 8 | 10 | 3 | 5 | 3 | 4 | 5 |
| Other Liabilities | 7 | 10 | 10 | 15 | 45 | 17 | 20 | 23 |
| Total Liabilities | 28 | 34 | 36 | 35 | 75 | 78 | 87 | 117 |
| Fixed Assets | 16 | 17 | 18 | 18 | 20 | 20 | 19 | 22 |
| CWIP | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 12 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 11 | 14 | 16 | 16 | 53 | 56 | 65 | 84 |
| Total Assets | 28 | 34 | 36 | 35 | 75 | 78 | 87 | 117 |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | 1 | 1 | 8 | 3 | -5 | 8 | 3 |
| Cash from Investing Activity | -2 | -3 | -2 | -2 | -4 | -1 | -1 | -14 |
| Cash from Financing Activity | 2 | 2 | 2 | -7 | 5 | 12 | -5 | 5 |
| Net Cash Flow | 0 | -0 | 0 | -0 | 4 | 6 | 2 | -6 |
| Free Cash Flow | -2 | -2 | -1 | 6 | -1 | -7 | 5 | -13 |
| CFO/OP | 25% | 81% | 38% | 292% | 64% | -24% | 92% | 17% |
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 51.16% |
| DIIs | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% |
| Public | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.92% | 48.93% | 48.74% |
| No. of Shareholders | 17,844 | 18,231 | 20,337 | 21,441 | 25,649 | 27,173 | 28,384 | 28,384 |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 345 | 245 | 318 | 132 | 187 | 120 | 98 | 148 |
| Inventory Days | 100 | 169 | 221 | 139 | 25 | 19 | 447 | 320 |
| Days Payable | 1,161 | 786 | 702 | 303 | 271 | 59 | 414 | 232 |
| Cash Conversion Cycle | -717 | -372 | -163 | -32 | -58 | 80 | 131 | 236 |
| Working Capital Days | 440 | 226 | 278 | 57 | 41 | 157 | 404 | 352 |
| ROCE % | 4% | 0% | 1% | 6% | 19% | 44% | 22% | 37% |
Shukra Pharmaceuticals L
₹2,465Cr.
₹55.9
₹65.3/26.3
68.4
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
Quarterly results
Profit & loss
Shareholding trend
Balance sheet
Cash flows
Key ratios
Frequently asked questions
What is the market cap of SHUKRA PHARMACEUTICALS L (SHUKRAPHAR)?
The reported market capitalisation for SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) is ₹2,465Cr. on Fincrux. Figures may update with market data and filings.
What is the current share price of SHUKRAPHAR?
The current price shown for SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) on Fincrux is ₹55.9 with a 52-week high/low of ₹65.3/26.3.
What is the P/E ratio of SHUKRA PHARMACEUTICALS L (SHUKRAPHAR)?
The stock P/E for SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) is 68.4 on Fincrux, with ROE at 28.9% and ROCE at 36.9%.
What were SHUKRAPHAR latest quarterly results?
For Jun 2026, SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) reported sales ₹24 Cr and net profit ₹15 Cr (figures in ₹ crore unless noted).
What are SHUKRAPHAR annual sales and net profit?
For TTM, SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) shows sales of ₹75 Cr and net profit of ₹36 Cr on the Fincrux profit & loss statement.
Who owns SHUKRA PHARMACEUTICALS L (SHUKRAPHAR)?
Latest shareholding for SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) on Fincrux: Promoters 51.16% (Aug 2026), DIIs 0.11% (Aug 2026), Public 48.74% (Aug 2026), No. of Shareholders 28,384% (Aug 2026).
Where can I find SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) financials?
SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.
Does Fincrux show SHUKRAPHAR balance sheet and cash flow?
Yes. The SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.